Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites

Experimental Parasitology

Volumn 134, Issue 2, 2013, Pages 235-243

  Alcantara, Laura M ^a   Kim, Junwon ^b   Moraes, Carolina B ^a   Franco, Caio H ^a   Franzoi, Kathrin D ^a   Lee, Sukjun ^a   Freitas Junior, Lucio H ^a   Ayong, Lawrence S ^a  

^a Institute Pasteur Korea   (South Korea)

^b Institut Pasteur Korea   (South Korea)

Author keywords

Chemosensitization potentials; P glycoprotein inhibitors; Plasmodium falciparum

Indexed keywords

ARTEMISININ; CHLOROQUINE; CHLORPHENIRAMINE; GEFITINIB; GLYCOPROTEIN P INHIBITOR; IMATINIB; MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN; TARIQUIDAR; ZOSUQUIDAR;

ANTIMALARIAL ACTIVITY; ARTICLE; BINDING SITE; CELL VACUOLE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMPETITION; DRUG POTENTIATION; DRUG TRANSPORT; ENZYME SUBSTRATE COMPLEX; GROWTH INHIBITION; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANTIMALARIALS; ARTEMISININS; BENZAMIDES; BORON COMPOUNDS; CHLOROQUINE; CHLORPHENIRAMINE; DIBENZOCYCLOHEPTENES; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; ERYTHROCYTES; FLUORESCENT DYES; HUMANS; MEFLOQUINE; P-GLYCOPROTEIN; PIPERAZINES; PLASMODIUM FALCIPARUM; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; QUINOLINES;

PLASMODIUM FALCIPARUM;

EID: 84876357714     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.03.022     Document Type: Article

References (56)

1. Adovelande J., Deleze J., Schrevel J. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum. Biochem. Pharmacol. 1998, 55:433-440.
2. Bray P.G., Martin R.E., Tilley L., Ward S.A., Kirk K., Fidock D.A. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol. Microbiol. 2005, 56:323-333.
3. Burger H., van Tol H., Boersma A.W., Brok M., Wiemer E.A., Stoter G., Nooter K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104:2940-2942.
4. Cabrera M., Natarajan J., Paguio M.F., Wolf C., Urbach J.S., Roepe P.D. Chloroquine transport in Plasmodium falciparum. 1. Influx and efflux kinetics for live trophozoite parasites using a novel fluorescent chloroquine probe. Biochemistry 2009, 48:9471-9481.
5. Cabrera M., Paguio M.F., Xie C., Roepe P.D. Reduced digestive vacuolar accumulation of chloroquine is not linked to resistance to chloroquine toxicity. Biochemistry 2009, 48:11152-11154.
6. Carrara V.I., Zwang J., Ashley E.A., Price R.N., Stepniewska K., Barends M., Brockman A., Anderson T., McGready R., Phaiphun L., Proux S., van Vugt M., Hutagalung R., Lwin K.M., Phyo A.P., Preechapornkul P., Imwong M., Pukrittayakamee S., Singhasivanon P., White N.J., Nosten F. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009, 4:e4551.
7. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
8. Cowman A.F. The P-glycoprotein homologues of Plasmodium falciparum: are they involved in chloroquine resistance?. Parasitol. Today 1991, 7:70-76.
9. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., Lwin K.M., Ariey F., Hanpithakpong W., Lee S.J., Ringwald P., Silamut K., Imwong M., Chotivanich K., Lim P., Herdman T., An S.S., Yeung S., Singhasivanon P., Day N.P., Lindegardh N., Socheat D., White N.J. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
10. Eechoute, K., Sparreboom, A., Burger, H., Franke, R.M., Schiavon, G., Verweij, J., Loos, W.J., Wiemer, E.A., Mathijssen, R.H., 2011. Drug transporters and imatinib treatment: implications for clinical practice. Clin. Cancer Res. 17, 406-415.
11. Elkind N.B., Szentpetery Z., Apati A., Ozvegy-Laczka C., Varady G., Ujhelly O., Szabo K., Homolya L., Varadi A., Buday L., Keri G., Nemet K., Sarkadi B. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 2005, 65:1770-1777.
12. Famin O., Ginsburg H. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemoglobin digestion in Plasmodium falciparum-infected erythrocytes. Biochem. Pharmacol. 2002, 63:393-398.
13. Fidock D.A., Nomura T., Cooper R.A., Su X., Talley A.K., Wellems T.E. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum. Mol. Biochem. Parasitol. 2000, 110:1-10.
14. Henry M., Alibert S., Orlandi-Pradines E., Bogreau H., Fusai T., Rogier C., Barbe J., Pradines B. Chloroquine resistance reversal agents as promising antimalarial drugs. Curr. Drug Targets 2006, 7:935-948.
15. Hobbs C., Duffy P. Drugs for malaria: something old, something new, something borrowed. F1000 Biol. Rep. 2009, 3:24.
16. Izumiyama S., Omura M., Takasaki T., Ohmae H., Asahi H. Plasmodium falciparum: development and validation of a measure of intraerythrocytic growth using SYBR Green I in a flow cytometer. Exp. Parasitol. 2009, 121:144-150.
17. Kelly J.X., Smilkstein M.J., Cooper R.A., Lane K.D., Johnson R.A., Janowsky A., Dodean R.A., Hinrichs D.J., Winter R., Riscoe M. Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob. Agents Chemother. 2007, 51:4133-4140.
18. Klonis N., Crespo-Ortiz M.P., Bottova I., Abu-Bakar N., Kenny S., Rosenthal P.J., Tilley L. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc. Natl. Acad. Sci. US A 2011, 108:11405-11410.
19. Koenderink J.B., Kavishe R.A., Rijpma S.R., Russel F.G. The ABCs of multidrug resistance in malaria. Trends Parasitol. 2010, 26:440-446.
20. Kuang Y.H., Shen T., Chen X., Sodani K., Hopper-Borge E., Tiwari A.K., Lee J.W., Fu L.W., Chen Z.S. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol. 2010, 79:154-161.
21. Kuhn Y., Sanchez C.P., Ayoub D., Saridaki T., van Dorsselaer A., Lanzer M. Trafficking of the phosphoprotein PfCRT to the digestive vacuolar membrane in Plasmodium falciparum. Traffic 2010, 11:236-249.
22. Lakshmanan V., Bray P.G., Verdier-Pinard D., Johnson D.J., Horrocks P., Muhle R.A., Alakpa G.E., Hughes R.H., Ward S.A., Krogstad D.J., Sidhu A.B., Fidock D.A. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 2005, 24:2294-2305.
23. Lambros C., Vanderberg J.P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 1979, 65:418-420.
24. Lehane, A.M., McDevitt, C.A., Kirk, K., Fidock, D.A., Degrees of chloroquine resistance in Plasmodium - is the redox system involved? Int. J. Parasitol. Drugs Drug Resist. 2, 47-57.
25. Lin S., Struve W.S. Time-resolved fluorescence of nitrobenzoxadiazole-aminohexanoic acid: effect of intermolecular hydrogen-bonding on non-radiative decay. Photochem. Photobiol. 1991, 54:361-365.
26. Martin R.E., Marchetti R.V., Cowan A.I., Howitt S.M., Broer S., Kirk K. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 2009, 325:1680-1682.
27. Masseno V., Muriithi S., Nzila A. In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid. Antimicrob. Agents Chemother. 2009, 53:3131-3134.
28. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 2002, 32:1655-1660.
29. Mu J., Ferdig M.T., Feng X., Joy D.A., Duan J., Furuya T., Subramanian G., Aravind L., Cooper R.A., Wootton J.C., Xiong M., Su X.Z. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol. 2003, 49:977-989.
30. Murray C.J., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., Fullman N., Naghavi M., Lozano R., Lopez A.D. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.
31. Nakornchai S., Konthiang P. Potentiation of antimalarial drug action by chlorpheniramine against multidrug-resistant Plasmodium falciparum in vitro. Parasitol. Int. 2006, 55:195-199.
32. O'Neill P.M., Barton V.E., Ward S.A. The molecular mechanism of action of artemisinin - the debate continues. Molecules 2010, 15:1705-1721.
33. Ozvegy-Laczka C., Cserepes J., Elkind N.B., Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat. 2005, 8:15-26.
34. Patel N.R., Rathi A., Mongayt D., Torchilin V.P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 2011, 416:296-299.
35. Peters W., Ekong R., Robinson B.L., Warhurst D.C., Pan X.Q. Antihistaminic drugs that reverse chloroquine resistance in Plasmodium falciparum. Lancet 1989, 2:334-335.
36. Petersen, I., Eastman, R., Lanzer, M., 2011. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett 585, 1551-1562.
37. Picot S., Olliaro P., de Monbrison F., Bienvenu A.L., Price R.N., Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 2009, 8:89.
38. Raj D.K., Mu J., Jiang H., Kabat J., Singh S., Sullivan M., Fay M.P., McCutchan T.F., Su X.Z. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J. Biol. Chem. 2009, 284:7687-7696.
39. Roberts L., Egan T.J., Joiner K.A., Hoppe H.C. Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum. Antimicrob. Agents Chemother. 2008, 52:1840-1842.
40. Rohrbach P., Sanchez C.P., Hayton K., Friedrich O., Patel J., Sidhu A.B., Ferdig M.T., Fidock D.A., Lanzer M. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J. 2006, 25:3000-3011.
41. Rubio J.P., Cowman A.F. Plasmodium falciparum: the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite. Exp. Parasitol. 1994, 79:137-147.
42. Sanchez C.P., Dave A., Stein W.D., Lanzer M. Transporters as mediators of drug resistance in Plasmodium falciparum. Int. J. Parasitol. 2010, 40:1109-1118.
43. Sanchez C.P., Rotmann A., Stein W.D., Lanzer M. Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Mol. Microbiol. 2008, 70:786-798.
44. Sanchez C.P., Stein W.D., Lanzer M. Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum. Trends Parasitol. 2007, 23:332-339.
45. Shah N.K., Alker A.P., Sem R., Susanti A.I., Muth S., Maguire J.D., Duong S., Ariey F., Meshnick S.R., Wongsrichanalai C. Molecular surveillance for multidrug-resistant Plasmodium falciparum, Cambodia. Emerg. Infect. Dis. 2008, 14:1637-1640.
46. Shen T., Kuang Y.H., Ashby C.R., Lei Y., Chen A., Zhou Y., Chen X., Tiwari A.K., Hopper-Borge E., Ouyang J., Chen Z.S. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009, 4:e7520.
47. Sidhu A.B., Uhlemann A.C., Valderramos S.G., Valderramos J.C., Krishna S., Fidock D.A. Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 2006, 194:528-535.
48. Sowunmi A., Oduola A.M., Ogundahunsi O.A., Salako L.A. Enhancement of the antimalarial effect of chloroquine by chloropheniramine in vivo. Trop. Med. Int. Health 1998, 3:177-183.
49. Strandberg L., Karolin J., Johansson L.B., Fa M., Aleshkov S., Ny T. Fluorescence studies on plasminogen activator inhibitor 1: reactive centre cysteine mutants remain active after fluorophore attachment. Thromb. Res. 1994, 76:253-267.
50. Summers R.L., Martin R.E. Functional characteristics of the malaria parasite's "chloroquine resistance transporter": implications for chemotherapy. Virulence 2010, 1:304-308.
51. Tarasova N.I., Seth R., Tarasov S.G., Kosakowska-Cholody T., Hrycyna C.A., Gottesman M.M., Michejda C.J. Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J. Med. Chem. 2005, 48:3768-3775.
52. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
53. van Schalkwyk D.A., Egan T.J. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist. Updat. 2006, 9:211-226.
54. Wellems T.E., Panton L.J., Gluzman I.Y., do Rosario V.E., Gwadz R.W., Walker-Jonah A., Krogstad D.J. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 1990, 345:253-255.
55. Wongsrichanalai C., Meshnick S.R. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. 2008, 14:716-719.
56. Yang C.H., Huang C.J., Yang C.S., Chu Y.C., Cheng A.L., Whang-Peng J., Yang P.C. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res. 2005, 65:6943-6949.